Metabolomic Embryo Profiles of Obese in Vitro Fertilization (IVF) Patients and Their Relationship With Polycystic Ovary Syndrome (PCO)
- Conditions
- InfertilityObesity
- Interventions
- Other: Culture medium metabolomic analysis
- Registration Number
- NCT01448863
- Lead Sponsor
- Instituto Valenciano de Infertilidad, IVI VALENCIA
- Brief Summary
The present study aims to elucidate if there is a metabolomic profile alteration in the embryos of obese women in order to understand if the reduced implantation rate observed in these patients is directly related to this factor. Furthermore, the investigators seek to establish if there is any difference between obese women with Polycystic Ovary Syndrome (PCO) and without PCO. The investigators compare these metabolomic profile embryos with embryos of egg-donation programme.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 28
- BMI > 30 kg/m2
- Age < 38 years old
- Non smokers
- First IVF cycle (groups 2 & 3, not Control group)
- Normal uterus (seen by ultrasound)
- normal basal hormonal profile(FSH,LH,estradiol,testosterone,androstenedione, insulin, SHBG, glucose, AMH)
- Antral follicle count(> 5 FA for each ovary)
- Menses every 25-35 days.
- < 5 or > 20 oocytes retrieved after stimulation cycle
- estradiol >3000 pg/ml or progesterone > 1,5 ng/ml on the hCG day.
- < 2 evolutive embryos in the culture medium.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description NO PCO Culture medium metabolomic analysis Obese women without Polycystic Ovarian Syndrome WITH PCO Culture medium metabolomic analysis Obese women with Polycystic Ovarian Syndrome CONTROL Culture medium metabolomic analysis Fertile women (egg-donors)
- Primary Outcome Measures
Name Time Method Metabolic profile of culture media of Day 3 embryos 3 days Determine differences in the metabolomic profile of the culture media of day 3 embryos, obtained after in vitro fertilization, according to the presence of obesity associated or not with polycystic ovary syndrome.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
IVI Valencia
🇪🇸Valencia, Spain